Alto Neuroscience

Recent news

• Rating change
  Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Aquestive Therapeutics (AQST) and Alto Neuroscience, Inc. (ANRO)
  TipRanks · 2026/6/26
• Rating change
  BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $37
  Market Newswire · 2026/8/13
• Rating change
  Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (AXSM), Guardian Pharmacy Services, Inc. Class A (GRDN) and Alto Neuroscience, Inc. (ANRO)
  TipRanks · 2026/6/17
• Rating change
  Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA), Alto Neuroscience, Inc. (ANRO) and Astrana Health (ASTH)
  TipRanks · 2026/7/14
• Rating change
  H.C. Wainwright Remains a Buy on Alto Neuroscience, Inc. (ANRO)
  TipRanks · 2026/6/25
• Rating change
  H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $55
  Market Newswire · 2026/8/17
• Rating change
  Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Alto Neuroscience, Inc. (ANRO) and Irhythm Technologies (IRTC)
  TipRanks · 2026/8/14
• Alto Neuroscience(ANRO.US) Officer Sells US$3.57 Million in Common Stock
  Market Newswire · 2026/10/2
• Rating change
  BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $37
  Market Newswire · 2026/8/13
• Rating change
  BTIG Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $28
  Market Newswire · 2026/7/14
• Analysts Are Bullish on Top Healthcare Stocks: Alto Neuroscience, Inc. (ANRO), Phreesia (PHR)
  TipRanks · 2026/10/3
• Alto Neuroscience, Inc. (ANRO) Receives a Buy From Jefferies
  TipRanks · 2026/8/13
• Rating change
  BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating
  Market Newswire · 2026/8/14
• Rating change
  Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Raises Target Price to $40
  Market Newswire · 2026/8/13
• Rating change
  H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50
  Market Newswire · 2026/6/25
• H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $55
  Market Newswire · 2026/9/22
• Rating change
  Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT)
  TipRanks · 2026/8/13
• Rating change
  Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and BridgeBio Pharma (BBIO)
  TipRanks · 2026/6/16
• William Blair Maintains Alto Neuroscience(ANRO.US) With Buy Rating
  Market Newswire · 2026/10/3
• Rating change
  JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $44
  Market Newswire · 2026/6/26

Headlines are aggregated automatically and are not independently verified or edited by our team.